The NMDA receptor in opioid-induced hyperalgesia: From neuroplasticity to perioperative prevention- Narrative review
DOI:
https://doi.org/10.61616/rvdc.v7i2.1828Palavras-chave:
opioid-induced hyperalgesia, NMDA receptor, remifentanil, ketamine, magnesiumResumo
Importance. Opioid-induced hyperalgesia (OIH) is a paradoxical increase in nociceptive sensitivity attributable to opioid exposure. In the perioperative period, recognition is difficult because pain from surgical injury, inadequate analgesia, pharmacological tolerance, and acute withdrawal produce overlapping phenotypes. Remifentanil is the most extensively investigated clinical model because it combines high potency, rapid titratability, and abrupt offset after infusion cessation. Objective. To examine the N-methyl-D-aspartate (NMDA) receptor as a point of convergence between opioid signalling, glutamatergic transmission, and pronociceptive neuroplasticity, and to critically appraise perioperative strategies intended to modulate this pathway. Observations. NMDA receptor activation requires the coincident binding of glutamate and glycine or D-serine, postsynaptic depolarisation, and relief of voltage-dependent Mg²⁺ block. The resulting Ca²⁺ influx activates protein kinase C, Ca²⁺/calmodulin-dependent protein kinase II, and transcriptional pathways that promote receptor phosphorylation and trafficking, long-term potentiation, descending facilitation, and central sensitisation. Glial activation, cytokines, and the NLRP3 inflammasome may further amplify this network. Ketamine and magnesium have the most direct mechanistic relationship with the NMDA receptor; methadone, dexmedetomidine, amantadine, buprenorphine, and regional analgesia offer complementary mechanisms. However, reductions in postoperative pain or opioid consumption do not, in isolation, demonstrate prevention of OIH. Clinical evidence remains limited by inconsistent definitions, heterogeneous comparators, small samples, and infrequent use of quantitative sensory testing (QST). Conclusions and Relevance. Prevention should be individualised and multimodal: avoid unnecessarily high opioid exposure, establish an analgesic bridge before discontinuing remifentanil, reduce nociceptive input, and reserve NMDA-modulating interventions for settings in which the anticipated benefit outweighs the risk. The NMDA receptor is a biologically coherent therapeutic target, but it is neither a diagnostic marker nor an exclusive explanation for OIH.
Referências
1. Wilson SH, Hellman KM, James D, Adler AC, Chandrakantan A. Mechanisms, diagnosis, prevention and management of perioperative opioid-induced hyperalgesia. Pain Manag. 2021;11(4):405-417. doi:10.2217/pmt-2020-0105
2. Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia—when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet. 2019;393(10180):1558-1568. doi:10.1016/S0140-6736(19)30430-1
3. Higgins C, Smith BH, Matthews K. Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis. Br J Anaesth. 2019;122(6):e114-e126. doi:10.1016/j.bja.2018.09.019
4. Roeckel LA, Le Coz GM, Gavériaux-Ruff C, Simonin F. Opioid-induced hyperalgesia: cellular and molecular mechanisms. Neuroscience. 2016;338:160-182. doi:10.1016/j.neuroscience.2016.06.029
5. Zhu K, Wen X, Mei X, Fang F, Zhang T. Mechanisms of remifentanil-induced postoperative hyperalgesia: a comprehensive review. Drug Des Devel Ther. 2025;19:7445-7457. doi:10.2147/DDDT.S550335
6. Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Short-term infusion of the μ-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain. 2003;106(1-2):49-57. doi:10.1016/S0304-3959(03)00276-8
7. Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000;93(2):409-417. doi:10.1097/00000542-200008000-00019
8. Weber L, Yeomans DC, Tzabazis A. Opioid-induced hyperalgesia in clinical anesthesia practice: what has remained from theoretical concepts and experimental studies? Curr Opin Anaesthesiol. 2017;30(4):458-465. doi:10.1097/ACO.0000000000000485
9. Trøstheim M, Eikemo M. Hyperalgesia in patients with a history of opioid use disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2024;81(11):1108-1117. doi:10.1001/jamapsychiatry.2024.2176
10. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145-161.
11. Hansen KB, Yi F, Perszyk RE, et al. Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol. 2018;150(8):1081-1105. doi:10.1085/jgp.201812032
12. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013;14(6):383-400. doi:10.1038/nrn3504
13. Antal M, Fukazawa Y, Eördögh M, et al. Numbers, densities, and colocalization of AMPA- and NMDA-type glutamate receptors at individual synapses in the superficial spinal dorsal horn of rats. J Neurosci. 2008;28(39):9692-9701. doi:10.1523/JNEUROSCI.1551-08.2008
14. Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain. 1991;44(3):293-299. doi:10.1016/0304-3959(91)90100-C
15. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 suppl):S2-S15. doi:10.1016/j.pain.2010.09.030
16. Curatolo M, Arendt-Nielsen L. Central sensitization and pain: pathophysiologic and clinical insights. Curr Neuropharmacol. 2024;22(1):15-22. doi:10.2174/1570159X20666221012112725
17. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci. 1994;14(4):2301-2312. doi:10.1523/JNEUROSCI.14-04-02301.1994
18. Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci. 2002;22(18):8312-8323. doi:10.1523/JNEUROSCI.22-18-08312.2002
19. Zhao M, Joo DT. Enhancement of spinal N-methyl-D-aspartate receptor function by remifentanil action at δ-opioid receptors as a mechanism for acute opioid-induced hyperalgesia or tolerance. Anesthesiology. 2008;109(2):308-317. doi:10.1097/ALN.0b013e31817f4c5d
20. Guntz E, Dumont H, Roussel C, et al. Effects of remifentanil on N-methyl-D-aspartate receptor: an electrophysiologic study in rat spinal cord. Anesthesiology. 2005;102(6):1235-1241. doi:10.1097/00000542-200506000-00025
21. Li S, Zeng J, Wan X, et al. Enhancement of spinal dorsal horn neuron N-methyl-D-aspartate receptor phosphorylation as the mechanism of remifentanil-induced hyperalgesia: roles of protein kinase C and calcium/calmodulin-dependent protein kinase II. Mol Pain. 2017;13:1744806917723789. doi:10.1177/1744806917723789
22. Qi F, Liu T, Zhang X, et al. Ketamine reduces remifentanil-induced postoperative hyperalgesia mediated by CaMKII-NMDA receptor signaling in the primary somatosensory cerebral cortex in mice. Neuropharmacology. 2020;162:107783. doi:10.1016/j.neuropharm.2019.107783
23. Drdla R, Gassner M, Gingl E, Sandkühler J. Induction of synaptic long-term potentiation after opioid withdrawal. Science. 2009;325(5937):207-210. doi:10.1126/science.1171750
24. Vanderah TW, Suenaga NM, Ossipov MH, Malan TP Jr, Lai J, Porreca F. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci. 2001;21(1):279-286. doi:10.1523/JNEUROSCI.21-01-00279.2001
25. Ji RR, Chamessian A, Zhang YQ. Pain regulation by non-neuronal cells and inflammation. Science. 2016;354(6312):572-577. doi:10.1126/science.aaf8924
26. Grace PM, Maier SF, Watkins LR. Opioid-induced central immune signaling: implications for opioid analgesia. Headache. 2015;55(4):475-489. doi:10.1111/head.12552
27. Yuan Y, Zhao Y, Shen M, et al. Spinal NLRP3 inflammasome activation mediates IL-1β release and contributes to remifentanil-induced postoperative hyperalgesia. Mol Pain. 2022;18:17448069221093016. doi:10.1177/17448069221093016
28. Zhu M, Yuan ST, Yu WL, Jia LL, Sun Y. CXCL13 regulates the trafficking of GluN2B-containing NMDA receptor via IL-17 in the development of remifentanil-induced hyperalgesia in rats. Neurosci Lett. 2017;648:26-33. doi:10.1016/j.neulet.2017.03.044
29. Horii Y, Matsuda M, Takemura H, Ishikawa D, Sawa T, Amaya F. Spinal and peripheral mechanisms individually lead to the development of remifentanil-induced hyperalgesia. Neuroscience. 2020;446:28-42. doi:10.1016/j.neuroscience.2020.08.014
30. Han X, Garcia Pinto L, Vilar B, McNaughton PA. Opioid-induced hyperalgesia and tolerance are driven by HCN ion channels. J Neurosci. 2024;44(6):e1368232023. doi:10.1523/JNEUROSCI.1368-23.2023
31. Jin Y, Mao Y, Chen D, et al. Thalamocortical circuits drive remifentanil-induced postoperative hyperalgesia. J Clin Invest. 2022;132(24):e158742. doi:10.1172/JCI158742
32. Dello Russo C, Di Franco V, Tabolacci E, et al. Remifentanil-induced hyperalgesia in healthy volunteers: a systematic review and meta-analysis of randomized controlled trials. Pain. 2024;165(5):972-982. doi:10.1097/j.pain.0000000000003119
33. Huang X, Cai J, Lv Z, et al. Postoperative pain after different doses of remifentanil infusion during anaesthesia: a meta-analysis. BMC Anesthesiol. 2024;24:25. doi:10.1186/s12871-023-02388-3
34. Joly V, Richebé P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology. 2005;103(1):147-155. doi:10.1097/00000542-200507000-00022
35. Comelon M, Raeder J, Stubhaug A, Nielsen CS, Draegni T, Lenz H. Gradual withdrawal of remifentanil infusion may prevent opioid-induced hyperalgesia. Br J Anaesth. 2016;116(4):524-530. doi:10.1093/bja/aev547
36. Wang X, Ida M, Uyama K, Naito Y, Kawaguchi M. Impact of different doses of remifentanil on chronic pain after video-assisted thoracic surgery: a randomized controlled trial. Medicine (Baltimore). 2023;102(30):e34442. doi:10.1097/MD.0000000000034442
37. Koppert W, Sittl R, Scheuber K, Alsheimer M, Schmelz M, Schüttler J. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology. 2003;99(1):152-159. doi:10.1097/00000542-200307000-00025
38. Wu L, Huang X, Sun L. The efficacy of N-methyl-D-aspartate receptor antagonists on improving the postoperative pain intensity and satisfaction after remifentanil-based anesthesia in adults: a meta-analysis. J Clin Anesth. 2015;27(4):311-324. doi:10.1016/j.jclinane.2015.03.020
39. Brinck ECV, Tiippana E, Heesen M, et al. Perioperative intravenous ketamine for acute postoperative pain in adults. Cochrane Database Syst Rev. 2018;12(12):CD012033. doi:10.1002/14651858.CD012033.pub4
40. Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):456-466. doi:10.1097/AAP.0000000000000806
41. Song JW, Lee YW, Yoon KB, Park SJ, Shim YH. Magnesium sulfate prevents remifentanil-induced postoperative hyperalgesia in patients undergoing thyroidectomy. Anesth Analg. 2011;113(2):390-397. doi:10.1213/ANE.0b013e31821d72bc
42. Wu EB, Wu KL, Hsu WT, Yuan WC, Chen KB. Pharmacological efficacy of intravenous magnesium in attenuating remifentanil-induced postoperative hyperalgesia: a systematic review and meta-analysis of randomized controlled trials. Pharmaceuticals (Basel). 2025;18(4):518. doi:10.3390/ph18040518
43. Tognoli E, Proto PL, Motta G, Galeone C, Mariani L, Valenza F. Methadone for postoperative analgesia: contribution of N-methyl-D-aspartate receptor antagonism: a randomized controlled trial. Eur J Anaesthesiol. 2020;37(10):934-943. doi:10.1097/EJA.0000000000001217
44. Machado FC, Vieira JE, de Orange FA, Ashmawi HA. Intraoperative methadone reduces pain and opioid consumption in acute postoperative pain: a systematic review and meta-analysis. Anesth Analg. 2019;129(6):1723-1732. doi:10.1213/ANE.0000000000004404
45. Murphy GS, Szokol JW, Avram MJ, et al. Clinical effectiveness and safety of intraoperative methadone in patients undergoing posterior spinal fusion surgery: a randomized, double-blinded, controlled trial. Anesthesiology. 2017;126(5):822-833. doi:10.1097/ALN.0000000000001609
46. Snijdelaar DG, Koren G, Katz J. Effects of perioperative oral amantadine on postoperative pain and morphine consumption in patients after radical prostatectomy: results of a preliminary study. Anesthesiology. 2004;100(1):134-141. doi:10.1097/00000542-200401000-00022
47. Wu Z, Yu J, Lin Q, et al. Effects of an intraoperative intravenous bolus dose of dexmedetomidine on remifentanil-induced postinfusion hyperalgesia in patients undergoing thyroidectomy: a randomized controlled trial. Anesth Analg. 2021;132(2):320-328. doi:10.1213/ANE.0000000000005003
48. Yuan Y, Sun Z, Chen Y, et al. Prevention of remifentanil-induced postoperative hyperalgesia by dexmedetomidine via regulating the trafficking and function of spinal NMDA receptors through protein kinase C and CaMKII. PLoS One. 2017;12(2):e0171348. doi:10.1371/journal.pone.0171348
49. Grape S, Kirkham KR, Frauenknecht J, Albrecht E. Intra-operative analgesia with remifentanil vs dexmedetomidine: a systematic review and meta-analysis with trial sequential analysis. Anaesthesia. 2019;74(6):793-800. doi:10.1111/anae.14657
50. Mercieri M, Palmisani S, De Blasi RA, et al. Low-dose buprenorphine infusion to prevent postoperative hyperalgesia in patients undergoing major lung surgery and remifentanil infusion: a double-blind, randomized, active-controlled trial. Br J Anaesth. 2017;119(4):792-802. doi:10.1093/bja/aex174
51. Martinez V, Beloeil H, Marret E, Fletcher D, Ravaud P, Trinquart L. Non-opioid analgesics in adults after major surgery: systematic review with network meta-analysis of randomized trials. Br J Anaesth. 2017;118(1):22-31. doi:10.1093/bja/aew391
52. Rivat C, Bollag L, Richebé P. Mechanisms of regional anaesthesia protection against hyperalgesia and pain chronicization. Curr Opin Anaesthesiol. 2013;26(5):621-625. doi:10.1097/01.aco.0000432511.08070.de
53. Koponen ME, Forget P. Pharmacological interventions for opioid-induced hyperalgesia: a scoping review of preclinical trials. J Clin Med. 2022;11(23):7060. doi:10.3390/jcm11237060
54. Xie WJ, Hong JS, Feng CF, Chen HF, Li W, Li YC. Pharmacological interventions for preventing opioid-induced hyperalgesia in adults after opioid-based anesthesia: a systematic review and network meta-analysis. Front Pharmacol. 2023;14:1199794. doi:10.3389/fphar.2023.1199794
55. Koponen ME, Naray E, Hales TG, Forget P. Pharmacological interventions for remifentanil-induced hyperalgesia: a systematic review and network meta-analysis of preclinical trials. PLoS One. 2024;19(12):e0313749. doi:10.1371/journal.pone.0313749
56. Rolke R, Baron R, Maier C, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. 2006;123(3):231-243. doi:10.1016/j.pain.2006.01.041
57. Katz NP, Paillard FC, Edwards RR. Review of the performance of quantitative sensory testing methods to detect hyperalgesia in chronic pain patients on long-term opioids. Anesthesiology. 2015;122(3):677-685. doi:10.1097/ALN.0000000000000530
58. Tarpin P, Serra E, Mahjoub Y, Martinez V. Early detection of opioid-induced hyperalgesia after an ICU stay using quantified sensory testing: an observational cohort case-control study. Br J Pain. 2025;19(5):337-345. doi:10.1177/20494637251356830
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Gloria Anabel Ortiz Cruz , Oscar Leonardo Castillo Cueva , Darlyn Dayana Arciniega Guerrero , Maritza Elizabeth Quezada Ochoa, Robert Jefferson Martínez Panchana , Darwin Daniel Campos González
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
